The core difference is straightforward. Mirena releases levonorgestrel, a progestin, and usually makes menstrual bleeding lighter over time. Paragard works through copper, contains no hormone, and often makes periods heavier and more crampy, especially early on. Both exceed 99% effectiveness, so mirena vs paragard counseling rarely turns on pregnancy prevention. It turns on bleeding, approved duration, and what the patient most wants to avoid.
Duration also separates them in US labeling. The 52 mg levonorgestrel system is labeled for pregnancy prevention for up to 8 years, while the copper T 380A device is labeled for up to 10 years. That difference shapes recall intervals, chart reminders, and how you frame long-term plans with a patient who may want pregnancy in five years.
The Short Version
- Mechanism differs: progestin thickens cervical mucus and thins endometrium; copper is toxic to sperm.
- Bleeding diverges early: hormonal devices usually lighten flow; copper usually increases flow and cramping.
- Approved duration differs: 8 years for the 52 mg hormonal system, 10 years for the copper device.
- Shared risks: expulsion, perforation, and a short post-insertion window of elevated infection risk.
- Counseling drives continuation: patients who expect the first three to six months stay with the method longer.
Mirena vs Paragard: Composition, Mechanism, and Approved Duration
Mirena is a levonorgestrel-releasing intrauterine system containing 52 mg of progestin in a polydimethylsiloxane reservoir on a T-shaped polyethylene frame. Release is highest after placement and declines steadily over the device life. Local progestin thickens cervical mucus, suppresses endometrial proliferation, and in some cycles inhibits ovulation. Systemic exposure stays low compared with oral contraceptives, which is why hormonal complaints are usually mild and transient. Our overview of how the Mirena IUD works covers the mechanism in more depth.
Paragard is a non-hormonal copper T 380A device with 380 mm² of exposed copper surface. Copper ions impair sperm motility and viability and create a local inflammatory environment hostile to fertilization. Nothing is absorbed systemically in a way that affects ovulation, so patients keep their natural cycle. For someone who wants to track ovulation, avoid progestin, or has declined hormones in the past, that is the decisive feature.
| Feature | Hormonal 52 mg system | Copper T 380A |
|---|---|---|
| Active agent | Levonorgestrel 52 mg | 380 mm² copper, no hormone |
| Labeled duration (US) | Up to 8 years for contraception | Up to 10 years |
| T-frame dimensions | Approximately 32 mm by 32 mm | Approximately 32 mm by 36 mm |
| Typical bleeding change | Lighter flow; amenorrhea in a minority | Heavier flow and more cramping |
| Additional labeled use | Heavy menstrual bleeding in patients choosing intrauterine contraception | None beyond contraception |
| Device-specific exclusions | Current breast cancer; acute liver disease or tumor | Wilson disease; copper allergy |
Verify duration and indications against current labeling before updating protocols, since approved intervals have been extended more than once; FDA prescribing information remains the controlling source. Our note on Mirena duration and labeling explains how to translate the current interval into recall workflow.
Bleeding Patterns Patients Actually Notice
Most comparison conversations turn on bleeding, not efficacy. With the 52 mg hormonal system, unscheduled spotting is common for the first three to six months. Flow then usually declines, and a meaningful minority reach amenorrhea by one year. That trajectory is the reason the device also carries an indication for heavy menstrual bleeding in patients who want intrauterine contraception.
The copper device has the opposite profile. Menstrual blood loss and dysmenorrhea often increase, with the largest change in the first few cycles. Many patients settle into a tolerable pattern, but bleeding and cramping remain the leading reasons for early removal in US cohorts. That single fact explains most of the difference in one-year continuation between the two devices.
Why it matters: Patients counseled to expect three to six months of change are far less likely to request early removal.
Screen for the baseline before choosing. Someone with iron deficiency, documented heavy menstrual bleeding, or disabling cramps is usually a poor candidate for copper. Someone who wants to keep a predictable natural cycle, or who has had a problematic progestin response, may prefer it. Background on levonorgestrel effects and safety is useful when a patient asks what the hormone actually does.
Patient Selection, Contraindications, and Screening
Both devices share most absolute contraindications. These include known or suspected pregnancy, current pelvic inflammatory disease or purulent cervicitis, untreated cervical gonorrhea or chlamydia, puerperal or post-septic-abortion sepsis, unexplained vaginal bleeding not yet evaluated, known cervical or endometrial cancer, gestational trophoblastic disease with persistent hCG elevation, pelvic tuberculosis, and a uterine cavity distorted enough to prevent correct placement. For the hormonal system, current breast cancer and acute liver disease are additional exclusions. For the copper device, Wilson disease and copper allergy apply.
Use a structured framework rather than memory. The CDC US Medical Eligibility Criteria set out category ratings by condition for both device classes, including postpartum timing, HIV status, and venous thromboembolism. Document which category applied when a patient has a relevant comorbidity.
Routine pre-placement ultrasound is not required. A bimanual exam and sounding establish uterine position and depth. STI testing, when indicated by risk, can be done the same day as placement; current guidance does not require delaying insertion while results are pending in asymptomatic patients.
Insertion, Expulsion, and Early Follow-Up
Insertion technique is similar for both devices, though inserter systems and loading steps differ and should be reviewed in the manufacturer instructions for use before first placement. Published guidance is not a substitute for supervised hands-on training. The CDC Selected Practice Recommendations cover timing, backup, and follow-up after intrauterine placement.
Expulsion is the complication clinics see most. Reported first-year rates generally fall in the low single digits to roughly one in ten, and estimates vary widely by study population. Risk is higher with immediate postpartum placement, heavy menstrual bleeding, severe dysmenorrhea, and prior expulsion. Several cohorts suggest copper devices are expelled somewhat more often than levonorgestrel systems, but the gap is modest and confounded by who receives each device.
What to tell the patient before they leave
Give a plain description of normal and abnormal. Cramping and spotting for days to weeks are expected. Increasing pain, fever, foul discharge, partial device protrusion, or a string that feels suddenly longer or shorter warrant evaluation. Ask the patient to confirm when backup contraception is needed, since that depends on device type and cycle timing at placement.
Complications, Recognition, and Escalation
Uterine perforation is uncommon, occurring on the order of one per 1,000 insertions in large cohort studies, with higher rates reported for placement during lactation and in the early postpartum period. Suspect it when sounding or insertion feels abnormal, when pain is severe, or when strings disappear. Imaging comes first: ultrasound, then abdominal radiograph if the device is not seen in the uterus. A device confirmed outside the cavity requires surgical referral.
Infection risk is concentrated in the first 20 days after placement and is low thereafter. Pelvic pain with fever, cervical motion tenderness, or purulent discharge in that window should be treated as possible pelvic inflammatory disease. Treatment can usually proceed with the device in place, with removal reserved for patients who do not improve.
Pregnancy with a device in situ is rare. When it happens, a larger proportion than usual is ectopic, so any positive test with pelvic pain needs prompt location assessment. Intrauterine pregnancy with visible strings is generally managed by early removal because of miscarriage and infection risk, which is a referral conversation rather than an office decision made alone.
Answering the Questions Patients Bring In
The mirena vs paragard choice is rarely about effectiveness, but patients arrive with specific questions. Short, direct answers work better than general reassurance.
- Does the copper device last 12 years? US labeling says up to 10 years. Extended use is described in international guidance but is off-label here.
- Is a copper IUD better than pills? It removes adherence from the equation, which raises typical-use effectiveness. It does not treat acne, cycle regularity, or heavy bleeding.
- Why do fewer patients choose copper? Mostly bleeding and cramping, not safety. Continuation at one year is usually lower for that reason.
- Which IUD is best? There is no single answer. Match the device to bleeding goals, hormone preference, and planned duration.
Emergency contraception comes up often. Copper device placement within five days of unprotected intercourse is recommended in CDC guidance as highly effective emergency contraception, but it is not an FDA-approved indication on the copper device label. If your clinic offers it, document the use as off-label and record the counseling.
Smaller-framed hormonal systems are the other common question. Lower-dose devices with narrower frames and shorter approved durations sit between these two options, and our comparison of Kyleena and Liletta device profiles covers where they fit. For patients who want long-acting coverage without a uterine procedure, the subdermal implant option is worth raising in the same visit.
Storage, Documentation, and Sourcing
Both devices ship sterile, single-use, in sealed packaging, and are stored at controlled room temperature. Inspect the seal and expiration date before opening, and discard any package that is damaged or previously opened. Record the lot number and expiry in the chart at every placement, since that is what supports any later recall or adverse event report.
Documentation should capture consent, device and lot, sounding depth, trimmed string length, tolerance of the procedure, and the follow-up plan. Clinics that standardize this on a template spend far less time reconstructing records later. Related workflow pieces sit in our clinic operations collection.
On procurement, Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013. Device listings such as the Mirena 52 mg intrauterine system show presentation and pack details for practice buyers.
For broader stocking decisions, browse the contraceptives product listings alongside the gynecology supplies range when you are building an insertion tray and backup inventory.
Counseling and Stocking Checklist
Use this before any mirena vs paragard counseling visit and at restock.
- Confirm pregnancy status and current bleeding pattern.
- Apply eligibility criteria to any relevant comorbidity and record the category.
- Match device to goals: hormone preference, bleeding target, years of coverage wanted.
- Set expectations for the first three to six months in writing.
- Inspect packaging for seal integrity and expiry before opening.
- Log lot and expiry plus sounding depth and string length.
- Give warning signs and a direct route back into the clinic.
- Diary the recall at the labeled replacement interval.
Neither device is the better one in the abstract. The copper option suits patients avoiding hormones who tolerate heavier periods; the levonorgestrel option suits patients who want lighter bleeding or have heavy menstrual bleeding. Say that plainly, then let the patient choose.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.







